These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2859993)

  • 1. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390.
    Creese I; Chen A
    Eur J Pharmacol; 1985 Feb; 109(1):127-8. PubMed ID: 2859993
    [No Abstract]   [Full Text] [Related]  

  • 2. The dopamine D1 receptor: biochemical and behavioral aspects.
    Andersen PH; Nielsen EB
    Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580
    [No Abstract]   [Full Text] [Related]  

  • 3. Benzazepines: structure-activity relationships between D1 receptor blockade and selected pharmacological effects.
    Iorio LC; Barnett A; Billard W; Gold EH
    Adv Exp Med Biol; 1986; 204():1-14. PubMed ID: 2947422
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective blockade of dopamine D-1 receptors by SCH 23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase in rats.
    Onali P; Olianas MC; Gessa GL
    Eur J Pharmacol; 1984 Mar; 99(1):127-8. PubMed ID: 6233165
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of prolonged treatment with neuroleptics on dopamine D-1 and D-2 receptor density in corpus striatum of mice.
    Hyttel J
    Acta Pharmacol Toxicol (Copenh); 1986 Nov; 59(5):387-91. PubMed ID: 2880451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and dopamine receptors binding affinity of 2-(3-fluoro-4-hydroxyphenyl)ethylamine and its N-alkyl derivatives.
    Cardellini M; Cingolani GM; Claudi F; Perlini V; Balduini W; Cattabeni F
    Farmaco Sci; 1988 Jan; 43(1):49-59. PubMed ID: 2899520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and behavioral effects of D1 dopamine antagonists.
    Barnett A; Iorio LC; McQuade R; Chipkin RE
    Adv Exp Med Biol; 1988; 235():137-44. PubMed ID: 2976247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
    Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
    J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.
    Seeman P; Niznik HB; Guan HC; Booth G; Ulpian C
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10156-60. PubMed ID: 2574862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue.
    Faedda G; Kula NS; Baldessarini RJ
    Biochem Pharmacol; 1989 Feb; 38(3):473-80. PubMed ID: 2563653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies.
    McQuade RD; Chipkin R; Amlaiky N; Caron M; Iorio L; Barnett A
    Life Sci; 1988; 43(14):1151-60. PubMed ID: 3050344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.
    Oblin A; Zivkovic B; Bartholini G
    Brain Res; 1987 Sep; 421(1-2):387-90. PubMed ID: 2446703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemical basis for the blockade of the D-1 dopamine receptor by SCH 23390.
    Itoh Y; Beaulieu M; Kebabian JW
    Eur J Pharmacol; 1984 Apr; 100(1):119-22. PubMed ID: 6144550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Adv Exp Med Biol; 1986; 204():29-52. PubMed ID: 2878579
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors.
    McGonigle P; Boyson SJ; Reuter S; Molinoff PB
    Synapse; 1989; 3(1):74-82. PubMed ID: 2521960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304
    [No Abstract]   [Full Text] [Related]  

  • 20. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
    Leslie CA; Bennett JP
    Brain Res; 1987 Jul; 415(1):90-7. PubMed ID: 2957025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.